Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients

Experimental and Clinical Transplantation

Volumn 10, Issue 6, 2012, Pages 586-591

  Nasiri Toosi, Zahra ^a   Dashti Khavidaki, Simin ^a,b   Nasiri Toosi, Mohsen ^b   Khalili, Hossein ^a,b   Jafarian, Ali ^b   Irajian, Hamideh ^b   Abdollahi, Alireza ^a   Sadrai, Sima ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Liver transplant; Oral; Pharmacokinetics; Sublingual; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG TROUGH LEVEL; FEMALE; GRAFT RECIPIENT; HUMAN; LIVER GRAFT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; SWALLOWING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84871292476     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0032     Document Type: Article

References (23)

1. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N EnglJ Med. 1994;331(17):110-1115.
2. Takamatsu Y, Ishizu M, Ichinose I, et al. Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant. 2001;28(4):421-423.
3. Hodak SP Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation.1998;66(4):535-537.
4. Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc. 2009;41 (3):840-842.
5. Reams BD, Palmer SM. Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. Am J Respir Med. 2002;1 (2):91-98.
6. Goorhuis JF, Scheenstra R, Peeters PM, Albers MJ. Buccal vs nasogastric tube administration of tacrolimus after pediatric liver transplantation. Pediatr Transplant. 2006; 10(1):74-77.
7. Hanger KM, Boettger RF Watkins KD, et al. A pharmacokinetic analysis of oral vs sublingual administration of tacrolimus in lung transplant recipients. Chest. 2010; 138(4)(suppl);542A.
8. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29 (6):404-430.
9. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Mont 2005;27(4):422-430.
10. Sam WJ, Tham LS, Holmes MJ, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet. 2006;45(1):59-75.
11. Regazzi MB, Rinaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit. 1999;21 (1):2-7.
12. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72(6):660-669.
13. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9(2): 130-137.
14. Jusko WJ, Piekoszewski W Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57(3):281-290.
15. The Monolix Software Web site. http://www.wfn.software.monolix.org. Accessed April 29, 2012.
16. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat & Data Anal. 2005;49(4): 1020-1038.
17. Collin C, Boussaud V Lefeuvre S, et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. Transplant Proc. 2010;42(10):4331-4337.
18. Romero I, Jimenez C, Gil F et al. Sublingual administration of tacrolimus in a renal transplant patient. J Clin Pharm Ther. 2008;33(1):87-89.
19. van de Plas A, Dackus J, Christiaans MH, Stolk LM, van Hooff JP Neef C. A pilot study on sublingual administration of tacrolimus. Transpl Int. 2009;22(3):358-359.
20. Verleden GM, Besse T Maes B. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. Transplantation. 2002;73(12): 1974-1976.
21. Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation. 1999;68(10):l482-1485.
22. Shimomura M, Masuda S, Saito H, et al. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res. 2002; 103(2):2I5-222.
23. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class 1 low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci. 2002;9I(3):719-729.